Research & Clinical Trials
Research Offering Hope and Changing Lives
Participating in research provides you access to medical advances well before they may become widely available for routine care―giving you a more active role in your health care. By building the foundation for better treatments and future outcomes, research also offers participants an opportunity to positively impact the community and future generations.
For these reasons, ask your care team about options to add research to your care plan.
Advancing the Treatment of COVID-19
Research teams at Spectrum Health are committed to the development and discovery of patient treatments for COVID-19. Spectrum Health physician researchers are collaborating with fellow scientists, locally and nationally, to bring innovative treatments and drugs to West Michigan patients.
Spectrum Health is participating in several COVID-19 clinical trials. For more information about any of these trials contact the Spectrum Health Office of Research and Education at firstname.lastname@example.org.
Clinical Trial of COVID-19 Convalescent Plasma of Outpatients (C3PO)
In partnership with the National Institutes of Health, the emergency department at Spectrum Health Butterworth Hospital in Grand Rapids, MI is participating in a clinical trial to determine whether a single dose of convalescent plasma prevents patients with COVID-19 from progressing from mild to severe illness.
“The focus of the C3PO trial is on patients with mild or moderate COVID-19 illness, who are at high risk of progressing to more severe illness that requires hospitalization,” said Joshua Reynolds, MD, MS, Spectrum Health emergency medicine. “By testing whether passive immunity with convalescent plasma is beneficial as an early outpatient treatment, we may be able to keep at-risk patients from getting sicker and subsequently needing more advanced care.”
Patients in the study with no more than seven days of symptoms that have mild illness severity, but also have risk factors for disease progression, are randomized to receive either convalescent plasma or a placebo.
Note: This research is, in part, funded by the National Institutes of Health (NIH) Agreement 1OT2HL156812-01. The views and conclusions contained on this website are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the NIH.
Spectrum Health is partnering with Regeneron Pharmaceuticals to enroll patients in the aSPIKE clinical trial, evaluating REGN-COV2, the company’s investigational antibody cocktail for the treatment of COVID-19. Only patients hospitalized at Spectrum Health Butterworth Hospital in Grand Rapids, MI who meet criteria can be enrolled in aSPIKE.
“Spectrum Health is participating in a trial to test the drug’s efficacy in hospitalized patients,” said Gordana Simeunovic, MD, Spectrum Health infectious disease. “It is a randomized, double-blind trial that measures the effect of adding the drug to the usual standard-of-care treatment we use in our hospital, compared to adding a placebo.”
As of October 2020, Spectrum Health is the only health system in West Michigan and one of only two in the state to offer this trial, known as the aSPIKE trial, for hospitalized COVID-19 patients. More information is available in the press release.
Convalescent Plasma Therapy
Plasma donations are urgently needed.
Spectrum Health was the first health system in Michigan to offer convalescent plasma therapy to patients with COVID-19. People who have recovered from COVID-19 and meet criteria, can donate plasma that will help patients with COVID-19.
To be eligible to donate, potential donors must:
- Have a confirmed diagnosis of COVID-19 by a physician and laboratory testing
- Be symptom-free for at least 14 days
Visit Versiti to start the plasma donation process. Additional criteria for donation is available here. A negative COVID-19 test result is not required. Thank you for considering a plasma donation and impacting the lives of patients today and into the future.